Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

The development history of new biomarkers for hepatitis B virus infection

[Research progress of biomarkers of hepatitis B virus and clinical significance]

Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection

[Application of the New Serum Markers in the Research and Development of Innovative Hepatitis B Drugs].

Cytokines and Chemokines in HBV Infection

Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers

Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management

HBV Biomarkers and Their Role in Guiding Treatment Decisions

Characteristics of HBV Novel Serum Markers Across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients

Clinical Significance of Novel Biomarkers to Predict the Natural Course of Hepatitis B Infection.

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection

New viral biomarkers for Hepatitis B: Are we able to change practice?

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B

Markers of Hepatitis B Virus Infection：current Application and Prospect

Application Value of Serum HBV RNA in Clinical Management of Chronic Hepatitis B

New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection

Biomarkers in Detection of Hepatitis C Virus Infection

[New Serological Markers As a Monitoring Indicator for Clinical Cure of Chronic Hepatitis B].